Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) has been given a $3.00 price objective by analysts at B. Riley in a research note issued to investors on Wednesday, December 27th. The firm currently has a “buy” rating on the biotechnology company’s stock. B. Riley’s price target would suggest a potential upside of 322.54% from the stock’s previous close.
A number of other research firms have also recently issued reports on ATNM. Maxim Group initiated coverage on shares of Actinium Pharmaceuticals in a research note on Thursday, September 14th. They issued a “buy” rating and a $3.00 target price for the company. Roth Capital restated a “buy” rating and issued a $6.00 price objective on shares of Actinium Pharmaceuticals in a research report on Monday, October 23rd. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Actinium Pharmaceuticals in a research report on Monday, October 23rd. Finally, Zacks Investment Research upgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research report on Monday, December 25th. Five analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $3.75.
Actinium Pharmaceuticals (NYSEAMERICAN ATNM) traded down $0.01 during mid-day trading on Wednesday, reaching $0.71. The company had a trading volume of 368,600 shares, compared to its average volume of 575,343. The firm has a market capitalization of $56.02, a P/E ratio of -1.51 and a beta of 41.30. Actinium Pharmaceuticals has a fifty-two week low of $0.54 and a fifty-two week high of $1.72.
ILLEGAL ACTIVITY WARNING: “B. Riley Reiterates $3.00 Price Target for Actinium Pharmaceuticals (ATNM)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/11/actinium-pharmaceuticals-atnm-given-a-3-00-price-target-by-b-riley-analysts.html.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.